Notice NOT-AA-21-033 from the NIH Guide for Grants and Contracts

Notice NOT-AG-21-026 from the NIH Guide for Grants and Contracts

Notice NOT-AG-21-025 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-DA-22-017 from the NIH Guide for Grants and Contracts. NIDA is interested in research that addresses research gaps related to PrEP and its use among substance users, with the goals of improving PrEP management and implementation. Current US Public Health Service PrEP guidelines recommend PrEP for people who inject drugs (PWID) and mention alcohol and illicit drug use as potential concerns for clinical management. Only one clinical trial has evaluated PrEP among PWID and systematic data regarding the broader use of PrEP among substance users are limited. There is a need to better understand the effects of substance use on PrEP effectiveness and better inform PrEP implementation among substance users. More systematic data are needed regarding the impact of substance use on PrEP management and adherence, along with investigating potential unintended consequences of PrEP use that may be unique to substance users. This RFA is restricted to projects conducted in the United States, although foreign components are permitted where they support domestic research in the United States. Applications are encouraged that propose research in states and counties identified in the US Governments Ending the HIV Epidemic (EtHE) initiative as described here: Ending the HIV Epidemic: A Plan for America https://www.hiv.gov/federal-response/ending-the-hiv-epidemic/overview. Applications to work in locales that are not included in the EtHE initiative must provide an epidemiologic justification for their inclusion in the research.

Funding Opportunity RFA-AG-22-017 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) aims to explore the role of adaptive immunity in Alzheimers disease and Alzheimers disease-related dementias (AD/ADRD). Specifically, the FOA seeks an understanding of brain immune surveillance, the generation of CNS-directed immune responses in neurodegenerative disorders, and the functional role of adaptive immunity in AD/ADRD onset and progression.

Notice NOT-GM-21-060 from the NIH Guide for Grants and Contracts

Funding Opportunity PA-21-264 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) issued by AHRQ invites grant applications for funding to conduct Large Health Services Research Demonstration and Dissemination Projects (R18) that propose to address strategies and approaches for prevention and reduction of Healthcare-Associated Infections (HAIs). This FOA describes the broad areas of HAI research for which funds are available to support Health Services Research Demonstration and Dissemination Projects.

Funding Opportunity RFA-AI-20-069 from the NIH Guide for Grants and Contracts. The purpose of this FOA is encourage and support the development of effective strategies for expanding the provision of HIV pre-exposure prophylaxis (PrEP) in sexually transmitted infection (STI) service settings in high priority jurisdictions identified by the presidential initiative, Ending the HIV Epidemic: A Plan for America. Funding for the fourth and fifth years (s) will be dependent upon achieving negotiated go/no go criteria and milestones.

Notice NOT-NR-21-003 from the NIH Guide for Grants and Contracts

Notice NOT-AG-21-027 from the NIH Guide for Grants and Contracts

Notice NOT-HG-21-034 from the NIH Guide for Grants and Contracts

Funding Opportunity PAS-21-245 from the NIH Guide for Grants and Contracts. Promoting a Basic Understanding of Chemical Threats to Skin (R34 Clinical Trial not allowed)

Funding Opportunity PAR-21-243 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages applications for investigator-initiated multi-site clinical trials (e.g. efficacy, effectiveness or pragmatic trials) to study the effects of complementary and integrative health approaches with physical and/or psychological therapeutic inputs (often called mind and body interventions) in NCCIH designated areas of high research priority. Clinical Coordinating Centers should develop and implement the proposed fully powered multi-site clinical trial. The objective of a Clinical Coordinating Center application is to present the scientific rationale and a comprehensive scientific and operational plan for the clinical trial. Clinical Coordinating Center applications are expected to describe plans for project management, participant recruitment and retention strategies, performance milestones, scientific conduct, and dissemination of results. Clinical Coordinating Center applications submitted under this FOA will utilize a two-phase, milestone-driven cooperative agreement (UG3/UH3) funding mechanism. In addition, an accompanying Data Coordinating Center application, submitted under PAR-XX-XXX proposing a data analysis and data management plan for the clinical project is required. Both a Clinical Coordinating Center application and a corresponding Data Coordinating Center (DCC) application need to be submitted simultaneously for consideration by NCCIH. For additional information about the mission, strategic vision, and research priorities of the NCCIH, applicants are encouraged to consult the NCCIH website: (https://nccih.nih.gov/about/plans). Applicants are encouraged to contact the appropriate the Scientific/Research contact for the area of science for which they are planning to develop an application prior to submitting to this FOA.

Funding Opportunity PAR-21-242 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA), utilizing the U24 grant funding mechanism, encourages applications for a collaborating Data Coordinating Center (DCC) application that accompanies an investigator-initiated multi-site clinical trial (Phase Ill and beyond) application submitted under TEMP-12554. The DCC application must be specific to the collaborating Clinical Coordinating Center (CCC) application. The objective of the DCC application is to propose a comprehensive plan that provides overall project coordination, and administrative, data management, and biostatistical support for the proposed clinical trial. Both a DCC application and a corresponding CCC application need to be submitted simultaneously for consideration by NCCIH. Trials for which this FOA applies must be relevant to the research mission of the NCCIH and considered a high priority by the Center. For additional information about the mission, strategic vision, and research priorities of the NCCIH, applicants are encouraged to consult the NCCIH website: (http://www.nccih.nih.gov). Applicants are encouraged to contact the appropriate the Scientific/Research contact for the area of science for which they are planning to develop an application prior to submitting to this FOA.

Funding Opportunity PAR-21-241 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications for investigator-initiated clinical trials of complementary and integrative health approaches with physical and/or psychological therapeutic inputs (often called mind and body interventions) in NCCIH-designated areas of high research priority. Applications submitted under this FOA are expected to propose a multi-site clinical trial to assess whether the intervention can be delivered with fidelity across sites; demonstrate feasibility of recruitment, accrual, and randomization of participants across sites; demonstrate participant adherence to the intervention, as well as retention of participants throughout the study across sites; and/or demonstrate feasibility of data collection across sites in preparation for a future multi-site trial. The need for multi-site feasibility trials are expected to be justified by sufficient preliminary data from previous single site feasibility or acceptability trial(s)or the published literature. This FOA will not support randomized clinical trials to determine efficacy or effectiveness. The data collected should be used to fill gaps in scientific knowledge necessary to develop a competitive fully powered multi-site clinical trial that has the potential to make a significant impact on public health Applicants are encouraged to contact the appropriate NCCIH Scientific/Research contact for the area of science for which they are planning to develop an application prior to submitting to this FOA..

Funding Opportunity PAR-21-240 from the NIH Guide for Grants and Contracts. The goal of this funding opportunity is to support early phase clinical trials of complementary and integrative health approaches with physical and/or psychological therapeutic inputs (often called mind and body interventions) for conditions that have been identified by NCCIH as high priority research topics. This funding opportunity is intended to support feasibility clinical trials, which will provide data that are critical for the planning and design of a subsequent controlled cohort study, clinical efficacy or effectiveness study, or a pragmatic trial. The data collected should be used to fill gaps in scientific knowledge necessary to develop a competitive full-scale clinical trial, including, but not limited to the following: examining feasibility and acceptability of interventions lacking published data; adapting an intervention to a specific population; refining the intervention to determine the most appropriate frequency or duration; determining feasibility of recruitment, retention and data collection procedures; refining and assessing the feasibility of protocolized multimodal interventions; or examining acceptability and adherence of control conditions. This FOA will not support randomized clinical trials to test or determine efficacy or effectiveness; nor will this FOA support repetition of feasibility or acceptability research that has been previously conducted in the same or similar patient population with the same or similar intervention. Applications that propose solely to write a protocol or manual of operations or to develop infrastructure for a clinical trial are not appropriate for this announcement. The subsequent larger trial should have the potential to make a significant impact on public health.

Notice NOT-DC-21-003 from the NIH Guide for Grants and Contracts

Notice NOT-DC-21-004 from the NIH Guide for Grants and Contracts

Notice NOT-HS-21-016 from the NIH Guide for Grants and Contracts

Notice NOT-MH-21-265 from the NIH Guide for Grants and Contracts